Ketamine Side Effects, Safety and Risks in Pennsylvania

Ketamine-class treatments can help some people with depression. They are also powerful dissociative anaesthetics with a real side-effect profile, a controlled-substance schedule, and monitoring rules that exist for a reason. This page is the plain version of those risks.

Common short-term effects

In treatment-resistant depression studies the most common side effects of Spravato were dissociation, dizziness, nausea, sedation, vertigo, reduced sense of touch, anxiety, lethargy, increased blood pressure, vomiting, feeling drunk, and headache. as of 30 Apr 2025 · U.S. Food and Drug Administration (source 1, opens in a new tab)The label lists a different set for the major-depressive-disorder-with-acute-suicidality indication. The two lists should not be conflated.

Spravato carries a boxed warning for sedation, dissociation, respiratory depression, abuse and misuse, and suicidal thoughts and behaviours — the same class of risks that justify the REMS clinic-only distribution system. as of 30 Apr 2025 · U.S. Food and Drug Administration (source 1, opens in a new tab)

During a session, blood pressure often rises for a while and then settles. Clinics check it for that reason. Nausea is common enough that many sites offer anti-nausea medicine. Tell staff early if you feel panicked, over-sedated, or like the room is too much — the dose rate can often be adjusted.

Dissociation — what people usually mean

Dissociation is a sense of detachment from your body, thoughts or surroundings. It can feel dreamlike, floaty, or frankly unpleasant. It is expected with these medicines at psychiatric doses, it is temporary for most people, and it is one of the reasons Spravato may only be given under observation.

A healthcare provider must monitor the patient for at least two hours after every Spravato dose before deciding they are ready to leave. as of 30 Apr 2025 · U.S. Food and Drug Administration (source 2, opens in a new tab)

Bladder and urinary effects

Long-term, high-frequency recreational ketamine use is associated with ketamine-induced ulcerative cystitis — painful bladder, frequency, urgency and, in severe cases, irreversible damage — and while psychiatric clinic doses are far lower, urinary symptoms should be reported early rather than ignored. as of 1 Jan 2023 · StatPearls / NCBI Bookshelf (source 1, opens in a new tab)Most cystitis case series describe chronic recreational exposure, not a standard six-infusion clinic course. Absence of a published clinic-dose incidence figure is not proof of zero risk.

If you develop new urinary pain, blood in the urine, or a sudden need to void constantly during a course of treatment, stop and call the clinic rather than waiting for the next booster. Clinics that never mention this risk are not doing you a favour.

Dependence, tolerance and withdrawal

Ketamine is a Schedule III controlled substance with accepted medical use and a recognised potential for psychological dependence, tolerance with repeated high-dose exposure, and a withdrawal picture that can include craving, sleep disturbance and mood changes after heavy non-medical use. as of 18 Jul 2026 · U.S. Drug Enforcement Administration (source 2, opens in a new tab)Schedule status describes abuse potential relative to other controlled drugs; it is not a prediction that a monitored clinic course will produce dependence.

Ketamine and its mirror-image form esketamine are Schedule III controlled substances under federal law, which means they have accepted medical uses but can be misused. as of 18 Jul 2026 · U.S. Drug Enforcement Administration (source 3, opens in a new tab)Esketamine has no separate DEA listing; it is covered as an enantiomer of ketamine, and the Spravato label carries the CIII designation.

A monitored clinic course is not the same exposure pattern as daily recreational use. Still, ask any programme that pushes frequent at-home dosing without review how they watch for escalating use — and walk away if they cannot answer.

Half-life and how long effects last

After intravenous dosing, ketamine's elimination half-life in adults is typically about two to three hours, with psychoactive effects that peak during the infusion and usually settle over the following hours — which is why clinics plan observation time and why next-day driving rules still apply after esketamine. as of 1 Jan 2022 · U.S. Food and Drug Administration (source 3, opens in a new tab)

After a Spravato dose you must not drive or operate machinery until the next day, following a restful night's sleep, so you need to arrange a ride home from every session. as of 30 Apr 2025 · U.S. Food and Drug Administration (source 6, opens in a new tab)

Feeling “mostly fine” an hour after a session is not permission to drive. The formal rule for Spravato is next-day driving only after restful sleep; many IV clinics apply the same caution.

Ketamine on a drug test

Standard workplace urine drug screens do not routinely include ketamine; detection usually requires a specific assay, and published detection windows after use are often on the order of a few days in urine depending on dose, frequency, metabolism and the laboratory method. as of 18 Jul 2026 · StatPearls / NCBI Bookshelf (source 3, opens in a new tab)Employers, courts and sports bodies may order expanded panels. If a drug test is pending, disclose prescribed treatment to the medical review officer rather than relying on a generalisation.

At-home and microdosing risk

At-home and microdosing ketamine programmes remove the on-site monitoring that clinic protocols use to catch blood-pressure spikes, severe dissociation, sedation and diversion — so the convenience trade-off is a real safety gap, not a minor difference in setting. as of 30 Apr 2025 · U.S. Food and Drug Administration (source 1, opens in a new tab)Spravato cannot be taken at home under the REMS. Compounded at-home racemic products are a different regulatory pathway and are not REMS-certified substitutes.

Pennsylvania is one of the stricter states here. A State Board of Medicine licensee must carry out an initial in-person physical examination before prescribing a controlled substance, apart from emergencies. A narrow telehealth exception added in December 2024 covers only buprenorphine and methadone in narcotic treatment programmes — it does not cover ketamine. In practice this means your first appointment cannot be done entirely remotely. as of 21 Dec 2024 · Pennsylvania Code and Bulletin (source 7, opens in a new tab)Federal DEA telemedicine flexibilities run separately and expire at the end of 2026, but they do not override a stricter state rule. We have not separately checked the parallel osteopathic board rule.

Microdosing content online often treats ketamine like a productivity supplement. That framing erases respiratory depression, blood-pressure spikes, dependence risk and diversion. If a seller will not discuss monitoring, that is the answer.

Pennsylvania Prescription Drug Monitoring Program (PA PDMP) in Pennsylvania

Prescription monitoring is three different questions — what must be reported, when a prescriber must check, and how that applies to ketamine — not one slogan.

What must be reported

Pennsylvania's Prescription Drug Monitoring Program was created by the ABC-MAP Act of 2014. Pharmacies and dispensing practitioners must report every Schedule II through Schedule V controlled substance they dispense, by the close of the next business day. as of 1 Jan 2017 · Pennsylvania Department of Health (source 7, opens in a new tab)The deadline is the close of the next business day, not 24 hours — across a weekend that is materially longer. Older material calls this system 'AWARxE', which is the former platform vendor's name; the Department of Health no longer uses it.

When a prescriber must check

A Pennsylvania prescriber must check the monitoring system in three situations: the first time they prescribe any controlled substance to a patient, whenever they have reason to believe a patient may be misusing or diverting drugs, and every single time they prescribe an opioid or a benzodiazepine. as of 1 Jan 2017 · Pennsylvania General Assembly (source 7, opens in a new tab)The Department of Health separately recommends checking before every controlled substance prescription as good practice. That is advice, not the legal trigger, and the two should not be confused.

Does this apply to ketamine?

Partly. Because ketamine is neither an opioid nor a benzodiazepine, a Pennsylvania prescriber is not required to check the monitoring system every time they prescribe it — only on the first controlled substance they prescribe you, or if they suspect misuse. Separately, ketamine and Spravato given to you inside a clinic are generally not recorded at all, because the law only covers medicine dispensed for you to take away. as of 18 Jul 2026 · Pennsylvania Department of Health (source 7, opens in a new tab)Take-home sublingual ketamine dispensed by a pharmacy is recorded. In-clinic infusions and Spravato generally are not.

When to seek urgent help

• Chest pain, severe headache, or neurological symptoms after a session
• Breathing that feels dangerously slow or shallow
• Suicidal thoughts that intensify, or any plan or intent to act on them
• Manic activation: drastically reduced need for sleep, racing speech, reckless behaviour
• Severe allergic reaction

If someone is in immediate danger, call 911. For a mental-health crisis, call or text 988, or text HOME to 741741.

If you are in crisis, call or text 988 to reach the 988 Suicide & Crisis Lifeline, or text HOME to 741741 to reach the Crisis Text Line. Both are free and available 24 hours a day. as of 18 Jul 2026 · 988 Suicide and Crisis Lifeline (source 1, opens in a new tab)

Related pages

• What a session involves
• Legal status and who may prescribe in Pennsylvania
• Bipolar-specific risks
• Who is typically assessed for treatment

Frequently asked questions